Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP... see more

Recent & Breaking News (TSXV:HEM)

Hemostemix Announces Clinical Trial Update and Contract with GlobeX Data to Encrypt its Communications with Regulatory Authorities

Newsfile March 18, 2021

Hemostemix Announces the Protocol First Contract and Warrant Repricing Approval

Newsfile February 11, 2021

Hemostemix Announces HS 12 - 01 Clinical Trial Completion of Subjects' Follow-Up Visits at the End of March and Warrants Extended and Repriced

Newsfile January 28, 2021

Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada

Newsfile January 22, 2021

Hemostemix Announces Grant of Stock Options

Newsfile January 4, 2021

Hemostemix Announces Closing of Unit Private Placement

Newsfile December 31, 2020

Hemostemix (TSXV:HEM) soars on placement’s price protection

Elise Kelly December 29, 2020

Hemostemix Announces Private Placement Update

Newsfile December 29, 2020

Hemostemix Announces Corporate Update

Newsfile December 23, 2020

Hemostemix Announces Closing of Existing Private Placement and Announces a New Private Placement

Newsfile December 18, 2020

InvestmentPitch Media Video Discusses Hemostemix Successfully Obtaining all Clinical Trial Data and Announcement of $2.5 Million Unit Offering - Video Available on Investmentpitch.com

Newsfile December 1, 2020

Hemostemix Announces Possession of All Clinical Trial Data and $2,500,000 Unit Financing

Canadian Press, with file by Stockhouse November 27, 2020

Hemostemix Announces Closing Of Private Placement

Canadian Press, with file by Stockhouse November 25, 2020

The story of how a biotech co. came to the aid of an ill 9-year-old boy

Featured Submission October 14, 2020

Hemostemix Announces Partial Win in Florida

Canadian Press, with file by Stockhouse October 8, 2020

Treatment for Vascular Diseases: Blood-Based Stem Cells are Preferred Medically and Scale Commercially

Stockhouse Editorial October 1, 2020

Hemostemix Announces Private Placement and Debt Settlement

Canadian Press, with file by Stockhouse September 29, 2020

Hemostemix Announces Dr. Pierre Leimgruber As Interim Chief Medical Officer

Canadian Press, with file by Stockhouse September 23, 2020

Hemostemix provides litigation update

Canadian Press, with file by Stockhouse September 22, 2020

Hemostemix Files Its Unaudited Condensed Consolidated Interim Financial Statements and Management Discussion and Analysis for the Three Months Ended March 31, 2020

Newsfile July 13, 2020